Q-omics provides the consensus-scored P2RX6P profile across patient tissues and cancer cell-line models. P2RX6P expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, P2RX6P is differentially expressed in 8, with the highest sampling consensus in BRCA. Additionally, P2RX6P RNA expression shows 6,502 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight BRCA, and ESCA as cancer lineages where P2RX6P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for P2RX6P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes P2RX6P survival associations across molecular data types. P2RX6P RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible P2RX6P RNA expression–survival associations across cancer types. High P2RX6P expression shows unfavorable associations in BRCA, LUAD, KIRC, UVM and KICH, but favorable associations in ACC. The BRCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for P2RX6P RNA expression.
This table summarizes P2RX6P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for P2RX6P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. P2RX6P shows lower tumor expression in BRCA, HNSC, STAD and PRAD and higher tumor expression in COAD and LUAD. The BRCA box plot shows higher P2RX6P RNA expression in normal versus tumor tissue (log2 FC = −1.040, t-test p < 0.001).
This table shows molecular features associated with P2RX6P in patient tissues and cancer cell lines. In patient samples, P2RX6P shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set.
